Wockhardt Founder Seeks GST Exemption on India-Discovered Antibiotics to Enhance Affordability

With Science and Technology Minister Jitendra Singh among the listeners, the founder of the country’s prominent pharmaceutical player said, “My request is that these antibiotics discovered in India must receive a similar kind of status. Effectively, it will become more affordable to the patient.” “I would have said the same thing had I been in his position,” Singh responded.

Also Read: Wockhardt Seeks DCGI Nod To Market Aspart Insulin Injection

Nafithromycin is the first macrolide antibiotic in 30 years to complete clinical development for community-acquired bacterial pneumonia. This achievement is significant given the stagnation in new macrolide antibiotic approvals since the late 1980s despite pneumonia causing several million deaths annually worldwide.

Nafithromycin or Miqnaf is globally the first-ever once-a-day three-days-only treatment for community-acquired bacterial pneumonia, including those caused by multi-drug resistant bugs.

Miqnaf is highly active against azithromycin and amoxicillin/clavulanate-resistant Pneumococci, as well as the entire range of pathogens involved in such infections and thus offering a monotherapy option.

Addressing the gathering, Singh cautioned physicians against indiscriminate prescription of antibiotics to patients as such practices could lead to drug resistance.

Also Read: USFDA Grants Fast-Track Designation to Wockhardt's Novel Antibiotic WCK 6777